ArticleObesity surgery2026
The Impact of Metabolic Bariatric Surgery on Inflammatory Bowel Disease Risk and Outcomes in Adults With Obesity: a Propensity-matched, Nationwide, Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe risk of de novo inflammatory bowel disease (IBD) after metabolic bariatric surgery (MBS) has been described, but the timing and severity of de novo IBD is unclear.
methodsUsing MarketScan Databases, patients with severe obesity undergoing Roux-en-Y-gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) were propensity-matched with patients with severe obesity without MBS (controls). Adjusted hazard ratio (aHR) assessed ulcerative colitis (UC) or Crohn's disease (CD) hazard <3 or ≥3 years from surgery or severe obesity. IBD severity was assessed using healthcare utilization-based proxies including medication exposure, IBD-related hospitalizations, and surgical interventions.
resultsThe cohort included 100,832 adults with MBS versus 376,855 controls (76.0% females, median age of 44 years). The incidence of IBD was higher in MBS cohort versus controls (61.2 vs. 44.4 per 100,000 adults/year). Within 3 years, patients with MBS had a 24% lower risk of de novo IBD versus controls (aHR: 0.76, 95% CI: 0.60-0.95). When stratified by surgery and IBD type, VSG had reduction in CD risk (aHR=0.46, 95% CI:0.22-0.96), while RYGB had reduction in UC risk (aHR=0.22, 95% CI:0.06-0.75). After 3 years, patients with MBS, particularly VSG, had greater than 2-fold increased risk of IBD (aHR=2.28, 95%CI: 1.02-5.06). Markers of treatment intensity and healthcare utilization did not significantly differ between groups overall; however, a higher proportion of UC patients in the MBS cohort underwent colectomy, though absolute event numbers were small. (8.70% vs 1.57%, p=0.03).
conclusionWhile MBS may lower IBD risk initially, IBD risk increases after 3 years, especially UC after VSG, and may be more severe as indicated by the higher proportion of colectomies for patients in the MBS cohort versus controls. Findings regarding treatment intensity should be interpreted cautiously, as objective measures of disease activity were not available in claims data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.